Oncotelic Therapeutics grants CEO up to 26,512 Series A preferred shares based on capital structure milestones

Oncotelic Therapeutics, Inc.

CEO Dr. Vuong Trieu receives 4,426 preferred shares (convertible to 4.426M common) for first milestone: converting $2.175M 2023 PPM Notes into 2025 Units.
Remaining 22,086 preferred shares vest upon three milestones: $350K debt from Mast Hill Fund with $45M market cap, conversion of $3.3M Autotelic loans, and repayment of $2.175M notes.
Each preferred share converts into 1,000 common shares; total potential dilution up to 26.512M common shares (approx. 4.99% of outstanding).
Agreement includes accelerated vesting upon termination without cause or change in control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.